(+)-Mosnodenvir
(+)-Mosnodenvir is an isomer of Mosnodenvir (HY-153810). Mosnodenvir (JNJ-1802) is an orally active pan serotype dengue virus (DENV) inhibitor, with EC50 values ranging from 0.057 to 11 nM for four dengue virus (DENV) serotypes. Mosnodenvir blocks viral replication by inhibiting the formation of complexes between two viral proteins, nonstructural protein 3 (NS3) and NS4B, thereby preventing the formation of new viral RNA. Mosnodenvir exhibits picomolar to nanomolar antiviral activity in vitro and has antiviral efficacy in mice and non-human primates.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2043343-94-6
- Formule: C26H22ClF3N2O6S
- Masse moléculaire:582.98
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Vero | CC50 |
2.9 μM
Compound: 9A, enantiomer 1
|
Cytotoxicity against African green monkey Vero cells infected with eGPF-labeled DENV2 16681 assessed as reduction in cell viability measured after 3 days by ATPlite assay
Cytotoxicity against African green monkey Vero cells infected with eGPF-labeled DENV2 16681 assessed as reduction in cell viability measured after 3 days by ATPlite assay
|
[PMID: 28105266] |
Chemical Information
-
CAS No. 2043343-94-6
-
Masse moléculaire 582.98
-
Formule C26H22ClF3N2O6S
-
SMILES
CS(C1=CC(OC)=CC(NC(C2=C(C=C(C=C2)Cl)OC)C(C(C3=C4)=CNC3=CC=C4OC(F)(F)F)=O)=C1)(=O)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
(+)-Mosnodenvir Related Classifications
HY-182317 Related Classifications
Powered by Bioz